ceftizoxime sodium - Profile

What are the generic drug sources for ceftizoxime sodium and what is the scope of patent protection?

Ceftizoxime sodium is the generic ingredient in three branded drugs marketed by Astellas and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ceftizoxime sodium

US Patents:	0
Tradenames:	3
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for ceftizoxime sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	063294-002	Mar 31, 1994		DISCN	No	No
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	050560-002	Sep 15, 1983		DISCN	No	No
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	063294-003	Mar 31, 1994		DISCN	No	No
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	050560-003	Sep 15, 1983		DISCN	No	No
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	050560-005	Mar 19, 1993		DISCN	No	No
Astellas	CEFIZOX	ceftizoxime sodium	INJECTABLE;INJECTION	050560-001	Sep 15, 1983		DISCN	No	No

Ceftizoxime Sodium: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 17, 2026

Ceftizoxime sodium, a third-generation cephalosporin antibiotic, exhibits a complex patent landscape characterized by expiring primary patents and emerging secondary patents. Its therapeutic efficacy against a broad spectrum of Gram-positive and Gram-negative bacteria underpins its continued market relevance, albeit facing competition from newer antimicrobials and increasing antimicrobial resistance challenges. Investment opportunities are contingent upon strategic patent management, market penetration in specific geographies, and the potential for novel delivery systems or combination therapies.

What is Ceftizoxime Sodium and Its Therapeutic Applications?

Ceftizoxime sodium is a parenteral antibiotic administered intravenously or intramuscularly. It functions by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to bacterial lysis. Its spectrum of activity includes:

• Gram-positive bacteria: Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae.
• Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia rettgeri, Serratia marcescens, Haemophilus influenzae (beta-lactamase negative strains), Neisseria gonorrhoeae.

It is indicated for the treatment of serious infections, including:

• Lower respiratory tract infections (pneumonia, bronchitis)
• Urinary tract infections (complicated and uncomplicated)
• Skin and skin structure infections
• Intra-abdominal infections (peritonitis, cholangitis, appendicitis)
• Bacterial meningitis (in specific patient populations and when indicated by susceptibility testing)
• Septicemia

Ceftizoxime sodium demonstrates good penetration into cerebrospinal fluid, making it a viable option for bacterial meningitis caused by susceptible organisms [1].

What is the Current Patent Status of Ceftizoxime Sodium?

The primary patents covering the composition of matter and initial synthesis of ceftizoxime sodium have long since expired. For instance, the original U.S. patents granted in the late 1970s and early 1980s are no longer in force. This has opened the market to generic manufacturers.

However, secondary patenting strategies continue to influence market dynamics. These often focus on:

• New formulations: Development of extended-release formulations, lyophilized powders with improved stability, or formulations for specific routes of administration.
• Manufacturing processes: Novel or improved synthetic routes that offer higher purity, reduced costs, or greater scalability.
• Combinations with other agents: Patents protecting combinations of ceftizoxime with beta-lactamase inhibitors or other antibiotics to broaden spectrum or overcome resistance.
• Methods of treatment: Claims directed to specific dosing regimens, treatment of particular patient subpopulations, or treatment of infections caused by specific resistant pathogens.

A search of patent databases reveals ongoing filings and granted patents related to these secondary aspects. For example, patents may claim specific crystallization methods, stable salt forms, or kits containing ceftizoxime and a beta-lactamase inhibitor. The lifespan of these secondary patents can extend for several years, providing periods of market exclusivity for innovators.

What are the Key Markets and Competitive Landscape for Ceftizoxime Sodium?

The market for ceftizoxime sodium is global, with significant consumption in North America, Europe, Asia, and Latin America. The competitive landscape is characterized by:

• Generic competition: Numerous generic manufacturers globally supply ceftizoxime sodium, driving down prices and contributing to a mature market. Key generic players include companies based in India, China, and some European countries.
• Branded products: While branded products like Cefizox® (GlaxoSmithKline) may still exist, their market share has diminished significantly due to patent expiry and generic erosion.
• Emerging resistance: The growing prevalence of multidrug-resistant (MDR) bacteria, including extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE), poses a significant challenge. Ceftizoxime sodium has limited efficacy against organisms producing ESBLs and is ineffective against CRE. This necessitates careful stewardship and susceptibility testing.
• Newer antibiotics: The development of novel antibiotics with broader spectra, activity against resistant organisms, or improved safety profiles (e.g., newer cephalosporins with broader Gram-negative coverage, carbapenems, newer beta-lactam/beta-lactamase inhibitor combinations) provides alternative treatment options.

Region	Key Market Drivers	Competitive Intensity	Patent Landscape Status
North America	Hospital use, broad-spectrum empirical therapy, generic availability.	High	Primary patents expired, secondary patents present.
Europe	Hospital use, cost-effectiveness, antibiotic stewardship programs.	High	Primary patents expired, secondary patents present.
Asia	Growing healthcare infrastructure, increasing infectious disease burden, generic supply.	Moderate to High	Primary patents expired, varied secondary patent activity.
Latin America	Increasing access to healthcare, generic drug penetration.	Moderate	Primary patents expired, lower secondary patent activity.

What are the Regulatory Considerations for Ceftizoxime Sodium?

Regulatory approval for ceftizoxime sodium is required in all target markets. Key regulatory considerations include:

• Abbreviated New Drug Application (ANDA) pathway: Generic manufacturers typically rely on the ANDA pathway in the U.S. to demonstrate bioequivalence to the reference listed drug (RLD). This process requires submission of abbreviated chemistry, manufacturing, and controls (CMC) data, along with bioequivalence studies [2].
• Drug Master Files (DMFs): Manufacturers of the active pharmaceutical ingredient (API) often file DMFs with regulatory agencies (e.g., FDA, EMA) to provide confidential detailed information about their manufacturing processes, facilities, and quality controls.
• Good Manufacturing Practices (GMP): Facilities manufacturing ceftizoxime sodium API and finished drug products must adhere to stringent GMP regulations to ensure product quality, safety, and efficacy.
• Labeling and prescribing information: Approved labeling must accurately reflect the approved indications, contraindications, warnings, precautions, adverse reactions, and dosing information, including any limitations related to antimicrobial resistance patterns.
• Post-marketing surveillance: Ongoing monitoring for adverse events and pharmacovigilance activities are required after product approval.
• Antimicrobial resistance stewardship: Regulatory bodies and healthcare organizations increasingly emphasize antimicrobial stewardship. This can influence prescribing patterns and potentially the market for older antibiotics if not used judiciously.

What are the Investment Fundamentals and Risks Associated with Ceftizoxime Sodium?

Investing in ceftizoxime sodium primarily targets the generic pharmaceutical market or opportunities related to secondary patenting.

Investment Fundamentals:

• Established demand: Ceftizoxime sodium remains a cost-effective option for treating susceptible bacterial infections, particularly in resource-limited settings and for certain hospital-acquired infections where it demonstrates activity.
• Generic market volume: The mature generic market offers consistent volume, provided manufacturing and supply chains are robust.
• Cost-effective API production: Companies with efficient and low-cost API manufacturing capabilities can achieve competitive pricing.
• Secondary patenting opportunities: Innovators can generate value through patents on improved formulations, manufacturing processes, or novel combination therapies that extend market exclusivity or create niche markets. For example, a patent on a stable lyophilized formulation that simplifies reconstitution for hospital use could offer a competitive advantage.
• Emerging market penetration: Expanding access and sales in emerging markets with growing healthcare expenditure can drive growth.

Key Investment Risks:

• Price erosion: Intense generic competition leads to significant and ongoing price declines, limiting profit margins for API and finished product manufacturers.
• Antimicrobial resistance: The increasing prevalence of resistant bacteria limits the clinical utility of ceftizoxime sodium, potentially reducing its demand and market share as preferred empirical therapy.
• Newer, more potent antibiotics: The continuous development of antibiotics with broader spectra or activity against resistant pathogens poses a constant threat of obsolescence or reduced use.
• Regulatory hurdles: Changes in regulatory requirements, increased scrutiny on API quality, or potential recalls due to manufacturing defects can impact market access and profitability.
• Supply chain disruptions: Dependence on specific raw material suppliers or geopolitical instability can disrupt production and supply, leading to stockouts and lost sales.
• Limited innovation potential: The basic composition of matter patent has expired, and the scope for truly novel therapeutic breakthroughs with ceftizoxime sodium itself is limited. Most innovation lies in incremental improvements.

What are the Future Outlook and Strategic Considerations?

The future outlook for ceftizoxime sodium is that of a mature, genericized antibiotic with enduring utility in specific clinical scenarios, but facing increasing pressure from antimicrobial resistance and newer agents.

Strategic Considerations for Investors:

• Focus on manufacturing efficiency: Companies that can optimize their manufacturing processes to achieve the lowest cost of goods sold will be best positioned in the generic market.
• Geographic diversification: Expanding into emerging markets where ceftizoxime sodium may be a more cost-effective first-line treatment option can provide growth avenues.
• Niche market development: Identifying specific indications or patient populations where ceftizoxime sodium retains a favorable risk-benefit profile, especially in combination with other agents.
• Exploiting secondary patents: For companies with R&D capabilities, investing in developing and patenting novel formulations, delivery systems, or combinations can create new revenue streams and extend market exclusivity.
• Partnerships for distribution: Collaborating with established distributors in target markets can facilitate market penetration and overcome logistical challenges.
• Robust quality control: Maintaining impeccable quality control and adhering to global GMP standards is paramount to avoid regulatory sanctions and maintain market trust.

The strategic approach to ceftizoxime sodium investment should prioritize operational excellence in manufacturing and distribution, coupled with targeted innovation in formulation or combination therapies, rather than relying on the discovery of novel therapeutic uses for the molecule itself.

Key Takeaways

• Ceftizoxime sodium's primary patents have expired, leading to a highly competitive generic market.
• Secondary patenting efforts focus on formulations, manufacturing processes, and combination therapies.
• Antimicrobial resistance and the emergence of newer antibiotics represent significant market challenges.
• Investment opportunities lie in cost-efficient manufacturing, emerging market penetration, and exploiting secondary patent protection.
• Risks include intense price competition, regulatory non-compliance, and the erosion of clinical utility due to resistance.

FAQs

1. What is the primary advantage of ceftizoxime sodium over older cephalosporins? Ceftizoxime sodium offers enhanced activity against a broader range of Gram-negative bacteria, including some that were less susceptible to earlier generations of cephalosporins. It also exhibits better stability against many beta-lactamases produced by these organisms.

2. Can ceftizoxime sodium be used to treat infections caused by ESBL-producing bacteria? Generally, no. Ceftizoxime sodium is often inactivated by the extended-spectrum beta-lactamases (ESBLs) produced by these bacteria, rendering it ineffective. Alternative antibiotic classes are typically required.

3. What is the typical route of administration for ceftizoxime sodium? Ceftizoxime sodium is administered parenterally, meaning it is given by injection, either intramuscularly or intravenously. It is not orally bioavailable.

4. Are there any specific contraindications for ceftizoxime sodium? The primary contraindication is known hypersensitivity to ceftizoxime sodium, other cephalosporins, or any component of the formulation. Caution is advised in patients with a history of penicillin allergy, as cross-reactivity can occur.

5. How does the cost of ceftizoxime sodium compare to newer antibiotics for serious infections? As a mature generic medication, ceftizoxime sodium is significantly less expensive than many newer antibiotics, particularly those developed to combat multidrug-resistant organisms. This cost-effectiveness is a key factor in its continued use, especially in settings with budget constraints.

Citations

[1] United States Pharmacopeia. (n.d.). Ceftizoxime Sodium. Retrieved from USP-NF, official monographs.

[2] U.S. Food & Drug Administration. (2023, September 25). Abbreviated New Drug Applications (ANDAs) for Generic Drugs. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generic-drugs/abbreviated-new-drug-applications-andas-generic-drugs